New Brunswick, N.J., May 25, 2023 –Rutgers Cancer Institute and RWJBarnabas Health today announced that data from SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL), and two abstracts from the neoadjuvant I-SPY 2 trial evaluating oral pacl*taxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer, have been selected as late-breaking presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held both in person in Chicago and online from June 2-6.
“We are thrilled to have physician-scientists from our health system participate in two innovative clinical trials selected for three late-breaking presentations at this year’s ASCO annual meeting, reinforcing our commitment to push the boundaries of science, provide patients with cutting-edge treatment options, and transform the way cancer is treated,” said Steven K. Libutti, MD, FACS, Director, Rutgers Cancer Institute and Senior Vice President, Oncology Services, RWJBarnabas Health. “As New Jersey’s only NCI-Designated Comprehensive Cancer Center, we strive to offer our patients comprehensive cancer care, including access to novel therapeutic advances and game-changing clinical trials that have the potential to save, extend and improve the quality of patients' lives, and reshape the future of cancer management.”
A total of 33 presentations and 9 publications have been accepted, highlighting research advances in several types of cancer, including lymphoma, pediatric, colorectal and breast cancer.
Oral Presentations
Abstract No.
Title
Presentation Date/Time
Location
Abstract 8006
LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.
Saturday, June 3, 2023, 3:15 p.m. CDT
Hall D2 & Live Stream
Abstract 9501
Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.
Monday, June 5, 2023,
3:00 p.m. CDT
Hall D1 & Live Stream
Abstract 1004
A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC).
Monday, June 5, 2023,
12:42 p.m. CDT
Hall B1 & Live Stream
Abstract 10008
Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.
Sunday, June 4, 2023,
12:09 p.m. CDT
S100a & Live Stream
Poster Presentations
Abstract No.
Title
Presentation Date/Time
Location
Abstract LBA612
Oral pacl*taxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I SPY 2 TRIAL.
Sunday, June 4, 2023,
8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract TPS3625
Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).
Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract TPS5103
SWOG S1823/CCTG GCC1: Translational observational investigational study of the liquid biomarker microRNA 371a-3p in newly diagnosed germ cell tumours—Real-world trial design, rapid accrual, and robust secondary use of data opportunities.
Saturday, June 3, 2023, 8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract TPS5109
HB-300, a novel arenavirus-based cancer immunotherapy in patients with metastatic castration-resistant prostate cancer.
Saturday, June 3, 2023, 8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract TPS5110
A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.
Saturday, June 3, 2023, 8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract TPS9594
A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM).
Saturday, June 3, 2023,
1:15 – 4:15 p.m. CDT
Hall A & On Demand
Abstract 532
A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2–positive breast cancer.
Sunday, June 4, 2023,
8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 2561
Clinical outcomes of immune checkpoint inhibitor treatment in patients with classic cold tumors identified to have a high tumor mutational burden via ctDNA.
Saturday, June 3, 2023,
8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 3085
Characterization of MCL-1 in patients with colorectal cancer (CRC): Expression, molecular profiles, and outcomes.
Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 3531
Chemotherapeutic sensitivity in colorectal cancer expressing low RNA of wild type hom*ologous recombination genes.
Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 3590
Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO).
Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 3622
Molecular profiling and characterization of the tumor immune microenvironment (TME) in appendiceal carcinoma (AC).
Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 4108
Comprehensive profiling of clock genes expression in hepatocellular carcinoma (HCC).
Monday, June 5, 2023,
8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 4144
Correlation of comprehensive molecular mapping of pancreatic ductal adenocarcinoma with XPO1 mRNA expression levels to potential clinical targets.
Monday, June 5, 2023,
8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 4145
Clinical genomic implications of transcriptional subtypes in pancreatic cancer.
Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 4150
KRAS G12C-mutated pancreatic cancer: Clinical outcomes based on chemotherapeutic regimen.
Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 4151
Molecular and clinical correlates of DSCR1 expression in pancreatic cancer (PDAC).
Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 4167
The five periampullary cancers: Not just different siblings but different families—An international multicenter cohort study.
Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 9548
A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced melanoma: Poor-prognosis subgroup analysis.
Saturday, June 3, 2023,
1:15 – 4:15 p.m. CDT
Hall A & On Demand
Abstract 10628
Learned lessons from a US-wide outreach program to broaden enrollment to the PROMISE Registry, a prostate cancer genetic registry.
Saturday, June 3, 2023, 1:15 – 4:15 p.m. CDT
Hall A & On Demand
Abstract 11018
Characterizing imposter syndrome among oncologists on social media.
Sunday, June 4, 2023, 8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 12075
Survivorship care and breast and cervical cancer screening.
Monday, June 5, 2023,
1:15 – 4:15 p.m. CDT
Hall A & On Demand
Poster Discussion Session
Abstract 2519
A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.
Saturday, June 3, 2023, 3:00 – 4:30 p.m. CDT
S100bc & On Demand
Abstract 3019
Preliminary safety and efficacy of tinengotinib tablets as monotherapy and combination therapy in advanced solid tumors: A phase Ib/II clinical trial.
Saturday, June 3, 2023,
4:11 p.m. CDT
S100bc & On Demand
Abstract 4020
Not all treated KRAS-mutant pancreatic adenocarcinomas are equal: KRAS G12D and survival outcome.
Monday, June 5, 2023,
11:30 a.m. – 1:00 p.m. CDT
Hall D2 & Live Stream
Abstract 7515
Response-adapted therapy (tx) with nivolumab plus brentuximab vedotin (nivo + BV) without autologous hematopoietic cell transplantation (auto-HCT) in children, adolescents, and young adults (CAYA) with low-risk relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL): CheckMate 744.
Monday, June 5, 2023,
1:49 p.m. CDT
E450 & On Demand
Abstract Discussion 4
Aging in Survivors of Pediatric Cancer
Monday, June 5, 2023, 5:36 p.m. CDT
S504 & On Demand
Abstract LBA520
Oral pacl*taxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
Sunday, June 4, 2023,
5:04 p.m. CDT
Hall B1 & Live Stream
Plenary Session
Abstract LBA4
SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin (BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).
Sunday, June 4, 2023,
2:53 p.m. CDT
Hall B1 & Live Stream
Publication Only
Session title
Presentation title
Presentation Date/Time
Location
Abstract e16073
Preoperative pembrolizumab for MSI high, EBV positive or PD-L1 positive locally advanced gastric cancer followed by surgery and adjuvant chemoradiation with pembrolizumab: Interim results of a phase 2 multi-center trial.
N/A
N/A
Abstract e18723
Assessment of how differences in efficacy and toxicity change healthcare professionals’ views on presentation of treatment options.
N/A
N/A
Abstract e15087
Safety and feasibility of the addition of a radiosensitizing methionine-restricted diet to radiation therapy.
N/A
N/A
Abstract e17618
Comparing sentinel lymphadenectomy and complete lymphadenectomy among obese patients (BMI >30) undergoing minimally invasive hysterectomy for early-stage endometrial cancer: An ACS-NSQIP database study.
N/A
N/A
Abstract e18605
Immediate inpatient toxicities associated with CAR T-cell therapy: Real world data from a national inpatient sample.
N/A
N/A
Abstract e24088
Barriers to offering female fertility preservation to pediatric and young adult oncology patients: A national survey of pediatric hematology oncology providers in the United States and Canada.
N/A
N/A
Abstract e12523
ctDNA detection before and during systemic therapy for inflammatory breast cancer.
N/A
N/A
Abstract e16079
Outcomes of Helicobacter pylori (HP) infection in esophageal cancer (EC): A 5-year nationwide analysis.
N/A
N/A
Abstract e19015
Pevonedistat plus belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome: A phase I multicenter study.
N/A
N/A
About Rutgers Cancer Institute
As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, together with RWJBarnabas Health, offers the most advanced cancer treatment options, including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex surgical procedures. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – patients have access to these cutting- edge therapies at Rutgers Cancer Institute in New Brunswick, Rutgers Cancer Institute at University Hospital in Newark, as well as through RWJBarnabas Health facilities. To make a tax-deductible gift to support the Cancer Institute, call 848-932-8013 or visit www.cinj.org/giving.
For journalists – contact:
Krista Didzbalis
Media Relations Assistant
732-507-8307
krista.didzbalis@rutgers.edu
For patient appointments/inquiries – contact:
844-CANCERNJ (844-226-2376)